Currently out of the existing stock ratings of Laura Sutcliffe, 27 are a BUY (50%), 27 are a HOLD (50%).

Laura Sutcliffe

Work Performance Price Targets & Ratings Chart

Analyst Laura Sutcliffe, currently employed at CITI, carries an average stock price target met ratio of 43.25% that have a potential upside of 24.7% achieved within 354 days.

Laura Sutcliffe’s has documented 100 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RMD, ResMed at 13-Jul-2026.

Wall Street Analyst Laura Sutcliffe

Analyst best performing recommendations are on RMD (RESMED).
The best stock recommendation documented was for GLPG (GALAPAGOS NV ADR) at 5/18/2020. The price target of $217.34 was fulfilled within 3 days with a profit of $5.27 (2.37%) receiving and performance score of 7.89.

Average potential price target upside

GLPG Galapagos NV ADR GSK GlaxoSmithKline PLC ADR NVS Novartis AG ADR GMAB Genmab AS SNY Sanofi ADR UCBJY UCB SA ADR RMD ResMed TLX Telix Pharmaceuticals BMY Bristol-Myers Squibb Company ARGX argenx NV ADR GILD Gilead Sciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 16-Oct-2020

$33

$4.87 (17.31%)

$32

7 months 29 days ago
(25-Feb-2026)

17/19 (89.47%)

$-1.02 (-3.00%)

59

Hold Since 09-Sep-2024

$40

$11.87 (42.20%)

$24

1 years 3 days ago
(21-Oct-2025)

1/2 (50%)

$8.57 (27.27%)

127

Hold Since 07-Mar-2024

$22

$-6.13 (-21.79%)

$31

1 years 8 months 10 days ago
(14-Feb-2025)

3/6 (50%)

$-3.44 (-13.52%)

376

Hold Since 19-Jan-2021

$125

1 years 9 months 1 days ago
(23-Jan-2025)

1/2 (50%)

$17.27 (16.03%)

63

Hold Since 14-Oct-2022

1 years 9 months 1 days ago
(23-Jan-2025)

2/6 (33.33%)

$2.78 (6.01%)

28

Show more analysts

Please expand the browser size to see the chart

Which stock is Laura Sutcliffe most bullish on?

Potential upside of $12.85 has been obtained for TLX (TELIX PHARMACEUTICALS)

Which stock is Laura Sutcliffe most reserved on?

Potential downside of -$17.86 has been obtained for RMD (RESMED)

What Year was the first public recommendation made by Laura Sutcliffe?

On 2016
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?